İrkeç, C. Et Al. 2017. Serum fractalkine levels in patients with vascular dementia, Alzheimer’s disease and mild cognitive impairment. WCN 2017 , (Kyoto, Japan), 663.

İrkeç, C., Kuz, T., Altıparmak, T., & Fıdan, I., (2017). Serum fractalkine levels in patients with vascular dementia, Alzheimer’s disease and mild cognitive impairment . WCN 2017 (pp.663). Kyoto, Japan

İrkeç, CEYLA Et Al. "Serum fractalkine levels in patients with vascular dementia, Alzheimer’s disease and mild cognitive impairment," WCN 2017, Kyoto, Japan, 2017

İrkeç, CEYLA Et Al. "Serum fractalkine levels in patients with vascular dementia, Alzheimer’s disease and mild cognitive impairment." WCN 2017 , Kyoto, Japan, pp.663, 2017

İrkeç, C. Et Al. (2017) . "Serum fractalkine levels in patients with vascular dementia, Alzheimer’s disease and mild cognitive impairment." WCN 2017 , Kyoto, Japan, p.663.

@conferencepaper{conferencepaper, author={CEYLA İRKEÇ Et Al. }, title={Serum fractalkine levels in patients with vascular dementia, Alzheimer’s disease and mild cognitive impairment}, congress name={WCN 2017}, city={Kyoto}, country={Japan}, year={2017}, pages={663} }